Hydroxyurea treatment effect on children with sickle cell disease and obstructive sleep apnea

Sleep Breath. 2017 Sep;21(3):697-701. doi: 10.1007/s11325-017-1458-9. Epub 2017 Jan 11.

Abstract

Background: While hydroxyurea is the mainstay of treatment for many of the comorbidities associated with sickle cell disease, its effect on obstructive sleep apnea has not been fully investigated. The purpose of this project is to help characterize the effects of hydroxyurea on obstructive sleep apnea in children with sickle cell disease and determine its therapeutic role in the condition.

Methods: Chart review was conducted on two pediatric patients with sickle cell disease who experienced resolution of obstructive sleep apnea following hydroxyurea administration.

Results: After undergoing approximately 11 months of hydroxyurea therapy, sleep apnea symptoms improved and obstructive sleep apnea resolution was confirmed by repeat polysomnography in both cases. This resolution was largely secondary to a reduction in the obstructive component of the apnea hypopnea index, highlighting a previously unreported association.

Conclusions: As adenotonsillectomy is associated with significant risks in patients with sickle cell disease, it appears reasonable to consider a period of observation for improvement of obstructive sleep apnea following hydroxyurea administration rather than directly proceeding with surgery.

Keywords: Adenotonsillectomy; Hydroxyurea; Obstructive sleep apnea; Pediatric; Polysomnography; Sickle cell disease.

Publication types

  • Case Reports

MeSH terms

  • Adenoidectomy / adverse effects
  • Anemia, Sickle Cell / complications*
  • Child
  • Child, Preschool
  • Humans
  • Hydroxyurea / therapeutic use*
  • Male
  • Polysomnography
  • Sleep Apnea, Obstructive / complications*
  • Sleep Apnea, Obstructive / surgery
  • Sleep Apnea, Obstructive / therapy*
  • Tonsillectomy / adverse effects

Substances

  • Hydroxyurea